Differin

Differin is a brand name of adapalene topical, approved by the FDA in the following formulation(s):

DIFFERIN (adapalene - cream; topical)

• 
  Manufacturer: GALDERMA LABS LP
  
  Approval date: May 26, 2000
  
  Strength(s): 0.1% ^[RLD][AB]

DIFFERIN (adapalene - gel; topical)

• 
  Manufacturer: GALDERMA LABS LP
  
  Approval date: May 31, 1996
  
  Strength(s): 0.1% ^[RLD][AB]


• 
  Manufacturer: GALDERMA LABS LP
  
  Approval date: June 19, 2007
  
  Strength(s): 0.3% ^[RLD]

DIFFERIN (adapalene - lotion; topical)

• 
  Manufacturer: GALDERMA R AND D
  
  Approval date: March 17, 2010
  
  Strength(s): 0.1% ^[RLD]

Has a generic version of Differin been approved?

A generic version of Differin has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Differin and have been approved by the FDA:

adapalene cream; topical

• 
  Manufacturer: FOUGERA PHARMS
  
  Approval date: June 30, 2010
  
  Strength(s): 0.1% ^[AB]

adapalene gel; topical

• 
  Manufacturer: GLENMARK GENERICS
  
  Approval date: July 1, 2010
  
  Strength(s): 0.1% ^[AB]


• 
  Manufacturer: PLIVA HRVATSKA DOO
  
  Approval date: June 2, 2010
  
  Strength(s): 0.1% ^[AB]

Note: No generic formulation of the following product is available.

• adapalene - lotion; topical

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Differin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
  Patent 7,579,377
  Issued: August 25, 2009
  Inventor(s): Graeber; Michael & Czernielewski; Janusz
  Assignee(s): Galderma Research & Development
  Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefore, advantageously topically applicable gels, creams or lotions.
  
  Patent expiration dates:
  
  
  • February 23, 2025
    
    ✓ 
    Patent use: TOPICAL TREATMENT OF ACNE VULGARIS
  
  



• 
  Pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
  Patent 7,737,181
  Issued: June 15, 2010
  Inventor(s): Graeber; Michael & Czernielewski; Janusz
  Assignee(s): Galderma Research & Development
  Dermatological disorders having an inflammatory or proliferative component, notably common acne, are treated with topically applicable pharmaceutical compositions containing about 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously formulated into topically applicable gels, preferably aqueous gels, creams, lotions or solutions.
  
  Patent expiration dates:
  
  
  • August 29, 2024
    
    ✓ 
    Drug product
  
  



• 
  Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphtoic acid for the treatment of dermatological disorders
  Patent 7,834,060
  Issued: November 16, 2010
  Inventor(s): Graeber; Michael & Czernielewski; Janusz
  Assignee(s): Galderma Research & Development
  Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.
  
  Patent expiration dates:
  
  
  • March 12, 2023
    
    ✓ 
    Patent use: TREATMENT OF ACNE
  
  



• 
  Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
  Patent 7,838,558
  Issued: November 23, 2010
  Inventor(s): Graeber; Michael & Czernielewski; Janusz
  Assignee(s): Galderma Research & Development S.N.C.
  Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.
  
  Patent expiration dates:
  
  
  • March 12, 2023
    
    ✓ 
    Drug product
  
  



• 
  Method for the treatment of acne using compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid
  Patent 7,868,044
  Issued: January 11, 2011
  Inventor(s): Graeber; Michael & Czernielewski; Janusz
  Assignee(s): Galderma Research & Development
  Dermatological disorders having an inflammatory or proliferative component, notably common acne, are treated with topically applicable pharmaceutical compositions containing about 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously formulated into topically applicable gels, preferably aqueous gels, creams, lotions or solutions.
  
  Patent expiration dates:
  
  
  • March 12, 2023
    
    ✓ 
    Patent use: TREATMENT OF ACNE
  
  



• 
  Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers
  Patent 7,998,467
  Issued: August 16, 2011
  Inventor(s): Mallard; Claire & Ferrara; Eve
  Assignee(s): Galderma Research & Development
  Cosmetic/dermatological compositions for topical application and useful for the treatment, e.g., of acne, contain, formulated into a physiologically acceptable medium, at least one naphthoic acid compound and at least one polyurethane polymer or derivative thereof, the at least one naphthoic acid compound being dispersed therein.
  
  Patent expiration dates:
  
  
  • May 31, 2028
    
    ✓ 
    Patent use: TREATMENT OF ACNE
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • March 17, 2013 - NEW DOSAGE FORM
  
  

See also...

• Differin Consumer Information (Drugs.com)
• Differin Cream Consumer Information (Wolters Kluwer)
• Differin Lotion Consumer Information (Wolters Kluwer)
• Differin Pads Consumer Information (Wolters Kluwer)
• Differin Solution Consumer Information (Wolters Kluwer)
• Differin Consumer Information (Cerner Multum)
• Differin Topical Advanced Consumer Information (Micromedex)
• Differin AHFS DI Monographs (ASHP)
• Adapalene Cream Consumer Information (Wolters Kluwer)
• Adapalene Lotion Consumer Information (Wolters Kluwer)
• Adapalene Pads Consumer Information (Wolters Kluwer)
• Adapalene Solution Consumer Information (Wolters Kluwer)
• Adapalene topical Consumer Information (Cerner Multum)
• Adapalene Topical Advanced Consumer Information (Micromedex)
• Adapalene AHFS DI Monographs (ASHP)

Bigeloil

Dosage Form: FOR ANIMAL USE ONLY
Bigeloil®

The Professional Liniment

Can be used before, during and after competition

Can also be used on dogs

Indications

For temporary relief of minor pain and swelling from sprains, strains, bruises, arthritis, overworked muscles and minor wounds.

Directions for Use

Rub onto sore area 2 to 3 times a day. For faster relief, rub with hair and wrap or blanket, especially overnight. Body Wash: mix 2 to 4 oz. with 1 gal. water, apply with sponge, avoid eyes. Brace: mix 2 to 3 oz. with 1 quart water, apply with sponge to warm horse up before workout, avoid eyes and saddle area. Arthritis: rub onto knees, hocks and fetlocks before workout, apply again at night and lightly wrap. Antiseptic: for minor wounds and skin irritations, apply full strength without rubbing.

Caution: Avoid contact with eyes and mucous membranes. Stop using if skin irritation develops or symptoms persist for more than 10 days. For severe injuries consult a veterinarian. For external use only. Keep out of reach of children.

Warning

Flammable. Keep away from fire, sparks and heated surfaces. Store at room temperature. For animal use only.

Active Ingredients

Menthol 1.25% W/W.

Other Ingredients

Alcohol, D&C Green #5, FD&C Yellow #5, Fragrance, Juniperberry Oil, Methyl Salicylate, Salicylic Acid, Thymol and Purified Water.

Distributed by:

W. F. Young, Inc.

302 Benton Drive

E. Longmeadow, MA 01028 USA

© WFY

www.absorbine.com

RM 342328-3

PRINCIPAL DISPLAY PANEL - 473 mL Bottle Label

Bigeloil®

THE PROFESSIONAL'S LINIMENT

• Reduces Pain & Swelling of Sore

Muscles, Joints, Legs & Arthritis

• Excellent Under Wraps

TOPICAL PAIN

RELIEF LIQUID

16 fl oz. (473 mL)

Bigeloil  menthol  liquid

Product Information Product Type OTC ANIMAL DRUG NDC Product Code (Source) 11444-130 Route of Administration TOPICAL DEA Schedule

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength Menthol (Menthol) Menthol 1.25 g  in 115 mL

Inactive Ingredients Ingredient Name Strength Alcohol   D&C Green NO. 5   FD&C Yellow NO. 5   Methyl Salicylate   Salicylic Acid   Thymol   Water

Product Characteristics Color      Score      Shape Size Flavor Imprint Code Contains

Packaging # NDC Package Description Multilevel Packaging 1 11444-130-01 473 mL In 1 BOTTLE, PLASTIC None 2 11444-130-02 946 mL In 1 BOTTLE, PLASTIC None 3 11444-130-03 3785 mL In 1 BOTTLE, PLASTIC None

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
Unapproved drug other		01/01/1997

Labeler - W. F. Young, Inc. (001114669)

Revised: 05/2010W. F. Young, Inc.

Miambutol

Miambutol may be available in the countries listed below.

Ingredient matches for Miambutol

Ethambutol

Ethambutol dihydrochloride (a derivative of Ethambutol) is reported as an ingredient of Miambutol in the following countries:

• Bosnia & Herzegowina


• Italy


• Turkey

International Drug Name Search

Citofen

Citofen may be available in the countries listed below.

Ingredient matches for Citofen

Tamoxifen

Tamoxifen citrate (a derivative of Tamoxifen) is reported as an ingredient of Citofen in the following countries:

• Bosnia & Herzegowina

International Drug Name Search

Terbinafin Actavis

Terbinafin Actavis may be available in the countries listed below.

Ingredient matches for Terbinafin Actavis

Terbinafine

Terbinafine hydrochloride (a derivative of Terbinafine) is reported as an ingredient of Terbinafin Actavis in the following countries:

• Austria


• Czech Republic


• Denmark


• Estonia


• Latvia


• Lithuania


• Slovakia


• Sweden


• Switzerland

International Drug Name Search

Larcadip

Larcadip may be available in the countries listed below.

Ingredient matches for Larcadip

Lercanidipine

Lercanidipine hydrochloride (a derivative of Lercanidipine) is reported as an ingredient of Larcadip in the following countries:

• Bangladesh

International Drug Name Search

Lugesteron

Lugesteron may be available in the countries listed below.

Ingredient matches for Lugesteron

Progesterone

Progesterone is reported as an ingredient of Lugesteron in the following countries:

• Finland

International Drug Name Search

Aceo

Aceo may be available in the countries listed below.

Ingredient matches for Aceo

Acemetacin

Acemetacin is reported as an ingredient of Aceo in the following countries:

• Taiwan

International Drug Name Search

Ampi-Ject

Ampi-Ject may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Ampi-Ject

Ampicillin

Ampicillin trihydrate (a derivative of Ampicillin) is reported as an ingredient of Ampi-Ject in the following countries:

• Netherlands

International Drug Name Search

Trapax

Trapax may be available in the countries listed below.

Ingredient matches for Trapax

Lorazepam

Lorazepam is reported as an ingredient of Trapax in the following countries:

• Argentina

International Drug Name Search

Grifonitren

Grifonitren may be available in the countries listed below.

Ingredient matches for Grifonitren

Nitrendipine

Nitrendipine is reported as an ingredient of Grifonitren in the following countries:

• Chile

International Drug Name Search

ratio-Fluoxetine

ratio-Fluoxetine may be available in the countries listed below.

Ingredient matches for ratio-Fluoxetine

Fluoxetine

Fluoxetine hydrochloride (a derivative of Fluoxetine) is reported as an ingredient of ratio-Fluoxetine in the following countries:

• Canada

International Drug Name Search

Verpir

Verpir may be available in the countries listed below.

Ingredient matches for Verpir

Acyclovir

Aciclovir is reported as an ingredient of Verpir in the following countries:

• Greece

International Drug Name Search

Rybix ODT Orally Disintegrating Tablets

Pronunciation: TRAM-a-dol
Generic Name: Tramadol
Brand Name: Rybix ODT

Rybix ODT Orally Disintegrating Tablets are used for:

Treating moderate to moderately severe pain.

Rybix ODT Orally Disintegrating Tablets are an analgesic. It works in certain areas of the brain and nervous system to decrease pain.

Do NOT use Rybix ODT Orally Disintegrating Tablets if:

• you are allergic to any ingredient in Rybix ODT Orally Disintegrating Tablets


• you have had a severe allergic reaction (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue) to codeine or another opioid (eg, morphine)


• you have phenylketonuria or severe or persistent diarrhea caused by antibiotic use


• you have suicidal thoughts or actions, or a history of alcohol or other substance abuse or addiction


• you are intoxicated with alcohol, opioids or narcotics (eg, codeine, morphine), or sedatives or sleeping medicines (eg, temazepam, zolpidem)


• you are taking carbamazepine, nefazodone, sodium oxybate (GHB), a thioxanthene (eg, thiothixene), or another product that contains tramadol

Contact your doctor or health care provider right away if any of these apply to you.

Before using Rybix ODT Orally Disintegrating Tablets:

Some medical conditions may interact with Rybix ODT Orally Disintegrating Tablets. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription (especially depression medicines) or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you have liver, kidney, or thyroid problems; a blockage in the bladder; diabetes; heart problems (eg, cor pulmonale); high blood pressure; pancreas problems; prostate problems; or metabolism problems


• if you have or have recently had any head injury, brain injury or tumor, increased pressure in the brain, or an infection of the brain or nervous system


• if you have a history of recent stomach or bowel surgery or any other stomach or bowel problems (eg, pain, inflammation, ulcers)


• if you have a history of lung or breathing problems (eg, asthma, chronic obstructive pulmonary disease [COPD]) or seizures (eg, epilepsy)


• if you drink alcohol; are going through withdrawal from alcohol or other substances; or if you have a history of alcohol or other substance abuse, mood or mental problems (eg, depression), or suicidal thoughts or actions

Some MEDICINES MAY INTERACT with Rybix ODT Orally Disintegrating Tablets. Tell your health care provider if you are taking any other medicines, especially any of the following:

• Alpha-2 receptor blockers (eg, yohimbine), azole antifungals (eg, ketoconazole), linezolid, lithium, macrolide antibiotics (eg, erythromycin), monoamine oxidase inhibitors (MAOIs) (eg, phenelzine, selegiline), nefazodone, quinidine, selective serotonin reuptake inhibitors (SSRIs) (eg, fluoxetine, paroxetine), serotonin-norepinephrine reuptake inhibitors (SNRIs) (eg, duloxetine), St. John's wort, tricyclic antidepressants (eg, amitriptyline), or "triptans" (eg, sumatriptan) because the risk of seizures or serotonin syndrome may be increased


• Anorexiants (eg, phentermine), butyrophenones (eg, haloperidol), cyclobenzaprine, furazolidone, loxapine, certain medicines for mental or mood disorders (eg, olanzapine), molindone, opioid pain medicines (eg, codeine, hydrocodone), phenothiazines (eg, promethazine), sleeping medicines (eg, zolpidem), sodium oxybate (GHB), thioxanthenes (eg, thiothixene), or tiagabine because the risk of side effects, including excessive drowsiness, trouble breathing, liver problems, or seizures, may be increased


• Carbamazepine because it may decrease Rybix ODT Orally Disintegrating Tablets's effectiveness and the risk of seizures may be increased


• Other products containing tramadol because they may increase the risk of Rybix ODT Orally Disintegrating Tablets's side effects


• Rifampin because it may decrease Rybix ODT Orally Disintegrating Tablets's effectiveness


• Anticoagulants (eg, warfarin) or digoxin because the risk of their side effects may be increased by Rybix ODT Orally Disintegrating Tablets

This may not be a complete list of all interactions that may occur. Ask your health care provider if Rybix ODT Orally Disintegrating Tablets may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Rybix ODT Orally Disintegrating Tablets:

Use Rybix ODT Orally Disintegrating Tablets as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Take Rybix ODT Orally Disintegrating Tablets by mouth with or without food.


• To open the blister pack, peel back the foil on the blister. Do NOT push the tablet through the foil.


• Do NOT chew, break, or split the tablet.


• To take Rybix ODT Orally Disintegrating Tablets, place the tablet in your mouth. Let it dissolve, and then swallow it with saliva. Rybix ODT Orally Disintegrating Tablets may be taken with or without water.


• If you miss a dose of Rybix ODT Orally Disintegrating Tablets and you are taking it regularly, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Rybix ODT Orally Disintegrating Tablets.

Important safety information:

• Rybix ODT Orally Disintegrating Tablets may cause drowsiness, dizziness, or vision changes. These effects may be worse if you take it with alcohol or certain medicines. Use Rybix ODT Orally Disintegrating Tablets with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.


• Do not drink alcohol while you are taking Rybix ODT Orally Disintegrating Tablets.


• Check with your doctor before you use medicines that may cause drowsiness (eg, sleep aids, muscle relaxers, narcotic pain medicines) while you are taking Rybix ODT Orally Disintegrating Tablets; it may add to their effects. Ask your pharmacist if you have questions about which medicines may cause drowsiness.


• Rybix ODT Orally Disintegrating Tablets may cause dizziness; alcohol, hot weather, exercise, or fever may increase this effect. To prevent it, sit up or stand slowly, especially in the morning. Sit or lie down at the first sign of this effect.


• Do NOT take more than the recommended dose or use for longer than prescribed without checking with your doctor. Doing so may increase the risk of seizures or breathing problems.


• Tell your doctor or dentist that you take Rybix ODT Orally Disintegrating Tablets before you receive any medical or dental care, emergency care, or surgery.


• Rybix ODT Orally Disintegrating Tablets may increase your risk of seizures. Your risk may be greater if you also have certain medical conditions, use certain medicines, or if you use a lot of alcohol. Talk to your doctor to see if you may have a greater risk of seizures while taking Rybix ODT Orally Disintegrating Tablets.


• Serotonin syndrome is a possibly fatal syndrome that can be caused by Rybix ODT Orally Disintegrating Tablets. Your risk may be greater if you take Rybix ODT Orally Disintegrating Tablets with certain other medicines (eg, "triptans," MAOIs, antidepressants). Symptoms may include agitation; confusion; hallucinations; coma; fever; fast or irregular heartbeat; tremor; excessive sweating; and nausea, vomiting, or diarrhea. Contact your doctor at once if you have any of these symptoms.


• This product contains phenylalanine. If you must have a diet that is low in phenylalanine, check with your doctor before you take Rybix ODT Orally Disintegrating Tablets.


• Use Rybix ODT Orally Disintegrating Tablets with caution in the ELDERLY; they may be more sensitive to its effects, especially constipation, weakness or tiredness, severe light-headedness, and indigestion.


• Rybix ODT Orally Disintegrating Tablets should not be used in CHILDREN younger than 16 years; safety and effectiveness in these children have not been confirmed.


• PREGNANCY and BREAST-FEEDING: Rybix ODT Orally Disintegrating Tablets has been shown to cause harm to the fetus. If you think you may be pregnant, contact your doctor. You will need to discuss the benefits and risks of taking Rybix ODT Orally Disintegrating Tablets while you are pregnant. Rybix ODT Orally Disintegrating Tablets are found in breast milk. Do not breast-feed while taking Rybix ODT Orally Disintegrating Tablets.

When used for long periods of time or at high doses, Rybix ODT Orally Disintegrating Tablets may not work as well and may require higher doses to obtain the same effect as when originally taken. This is known as TOLERANCE. Talk with your doctor if Rybix ODT Orally Disintegrating Tablets stops working well. Do not take more than prescribed.

Some people who use Rybix ODT Orally Disintegrating Tablets for a long time without a break may develop a physical need to continue taking it. This is known as physical DEPENDENCE.

If you suddenly stop taking Rybix ODT Orally Disintegrating Tablets, you may experience WITHDRAWAL symptoms including anxiety; diarrhea; fever, runny nose, or sneezing; goose bumps and abnormal skin sensations; nausea; vomiting; pain; rigid muscles; rapid heartbeat; seeing, hearing, or feeling things that are not there; shivering or tremors; sweating; and trouble sleeping.

Possible side effects of Rybix ODT Orally Disintegrating Tablets:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Constipation; diarrhea; dizziness; drowsiness; dry mouth; headache; increased sweating; indigestion; mild itching; nausea; trouble sleeping; vomiting; weakness.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; unusual hoarseness); agitation; chest pain; confusion; difficult or painful urination; disorientation; excessive sweating; fainting; fast or irregular heartbeat; fever; hallucinations; loss of coordination; mood or mental changes (eg, depression); red, blistered, swollen, or peeling skin; seizures; severe dizziness or light-headedness; severe nausea, vomiting, or diarrhea; severe or persistent headache; slow or shallow breathing; suicidal thoughts or behaviors; tremor; vision problems.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Rybix ODT side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include bluish skin; cold, clammy skin; difficult, shallow, or slow breathing; drowsiness leading to unresponsiveness or coma; excessive sweating; limp muscles; pinpoint pupils; seizures; slow or irregular heartbeat.

Proper storage of Rybix ODT Orally Disintegrating Tablets:

Store Rybix ODT Orally Disintegrating Tablets at 77 degrees F (25 degrees C). Brief storage at temperatures between 59 and 86 degrees F (15 and 30 degrees C) is permitted. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Rybix ODT Orally Disintegrating Tablets out of the reach of children and away from pets.

General information:

• If you have any questions about Rybix ODT Orally Disintegrating Tablets, please talk with your doctor, pharmacist, or other health care provider.


• Rybix ODT Orally Disintegrating Tablets are to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Rybix ODT Orally Disintegrating Tablets. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Rybix ODT resources

• Rybix ODT Side Effects (in more detail)
• Rybix ODT Use in Pregnancy & Breastfeeding
• Rybix ODT Drug Interactions
• 0 Reviews for Rybix ODT - Add your own review/rating

Compare Rybix ODT with other medications

• Back Pain
• Pain

ratio-Mometasone

ratio-Mometasone may be available in the countries listed below.

Ingredient matches for ratio-Mometasone

Mometasone

Mometasone 17-(2-furoate) (a derivative of Mometasone) is reported as an ingredient of ratio-Mometasone in the following countries:

• Canada

International Drug Name Search